Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin to prevent worsening of LV volumes after MI
NCT05020704Phase 3Active, not recruiting
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in myocardial infarction (MI), sponsored by NHS Greater Glasgow and Clyde. Started Sep 2022; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05020704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020704.